Dose-Intense Paclitaxel: Déjà Vu All Over Again?
- 1 August 2003
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (15) , 2810-2814
- https://doi.org/10.1200/jco.2003.05.099
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Phase III Trial of Paclitaxel at Two Dose Levels, the Higher Dose Accompanied by Filgrastim at Two Dose Levels in Platinum-Pretreated Epithelial Ovarian Cancer: An Intergroup StudyJournal of Clinical Oncology, 2003
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- Mathematics and Oncology: A Match for Life?Journal of Clinical Oncology, 2003
- High-Dose Chemotherapy and Stem Cell Support for Breast CancerDrugs & Aging, 2002
- Theoretical Concepts and the Emerging Role of Taxanes in Adjuvant TherapyThe Oncologist, 2001
- The clinical pharmacology of the oral fluoropyrimidinesCurrent Problems in Cancer, 2001
- The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?European Journal Of Cancer, 2000
- Paclitaxel (Taxol)New England Journal of Medicine, 1995
- A saturation threshold for taxol cytotoxicity in human glial and neuroblastoma cellsAnti-Cancer Drugs, 1993
- Predicting the course of Gompertzian growthNature, 1976